MaxCyte sees FY25 core business revenue up 8%-15%

The company said, “Core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments. MaxCyte (MXCT) expects to end 2025 with $160 million in total cash, cash equivalents and investments.”